Yasmine Wasfi - 20 Oct 2025 Form 4 Insider Report for Savara Inc (SVRA)

Reporting relationship: Chief Medical Officer
Issuer ticker: SVRA
Reported as of: 20 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Oct 2025, 20:47:47 UTC
Prior SEC filing: 22 Oct 2025
Next SEC filing: 04 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Kate McCabe as attorney-in-fact for Yasmine Wasfi

Key filing fact

Yasmine Wasfi filed Form 4 for Savara Inc (SVRA) on 22 Oct 2025.

Key facts

This page summarizes Yasmine Wasfi's Form 4 filing for Savara Inc (SVRA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 22 Oct 2025, 20:47.

Change

Previous filing in this sequence was filed on 22 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002092127 Primary reporting owner

Wasfi Yasmine

Relationship: Chief Medical Officer
Address: ONE SUMMIT SQUARE,, 1717 LANGHORNE NEWTOWN ROAD, SUITE 300, LANGHORNE
Signature: /s/ Kate McCabe as attorney-in-fact for Yasmine Wasfi
Signature date: 22 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SVRA transaction

Common Stock

Award

Transaction value: $0
Shares: +35,000
Change %: +23%
Price: $0.000000
Shares after: 190,000
Date: 20 Oct 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SVRA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +70,000
Change %
Price: $0.000000
Shares after: 70,000
Date: 20 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 70,000
Exercise price: $4.11
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units ("RSUs") that vest in full on October 17, 2027, subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Footnote F2

The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of October 17, 2025, subject to the reporting person's continued service with the Issuer.